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ABSTRACT
Causal Inference Between
Adiponectin, Body Mass Index, and Aminotransferase Levels
: a Mendelian Randomization Analysis
Hong, Seri
Dept. of Public Health
The Graduate School
Yonsei University
Background:
An association between obesity and hepatocyte injury, or liver disease, has been 
suggested continuously. Adiponectin’s potential role in hepatocyte protection against 
lipid accumulation, fibrosis, or cirrhosis has also been proposed. Although many studies
on the relationship between obesity, adiponectin and liver disease have been conducted, a 
causal relationship has not been established due to the limitations of observational studies. 
In the present study, we investigated whether obesity and adiponectin levels are causally 
associated with abnormal aminotransferases levels by applying a Mendelian 
randomization study design using the population-based Korean Cancer Prevention Study-
II (KCPS-II) Biobank Cohort data. 
xMaterials and Methods:
Among the KCPS-II Biobank subcohort, 3,793 healthy Koreans without the hepatitis 
virus infection and extremely high aminotransferase levels were included as the study 
population. Genome-wide association study (GWAS) was performed to select highly 
associated SNPs with adiponectin levels and body mass index (BMI). Both of single
representative SNPs and the weighted genetic risk scores for each intermediate phenotype
were used as instrumental variables for the Mendelian randomization analysis. Their
causal effects on the liver enzyme abnormalities were evaluated with Wald estimator and 
two-stage least squares method.
Results: 
Seven independent SNPs and rs4783244 in CDH13 gene associated with adiponectin 
levels as well as 13 SNPs including rs2030323 of the BDNF gene for BMI were selected
as genetic instrumental variables from GWAS analysis. All single SNPs and weighted 
genetic risk scores used in the analysis were strongly associated with each intermediate 
phenotype. The association between adiponectin level and liver enzyme elevation was 
found to be insignificant according to Mendelian randomization analysis, which implied
that no causal relationship between serum adiponectin level and liver injury could be
found. However, there was a significant positive association between BMI and liver 
enzyme levels in both conservative regression and Mendelian randomization analysis, 
indicating the causal effect of obesity on liver enzyme elevation, which is representative 
of liver injury.
xi
Conclusion:
The present study suggests a possible pathogenetic mechanism that starts from excessive 
adiposity and is linked to liver injury, with obesity as a causal factor and decreased 
adiponectin levels as an intermediate result rather than a cause. This result implies that 
loss of adiposity is essential and should be the primary target for preventive and 
therapeutic approaches regarding obesity-related liver damage or metabolic liver diseases.
Keywords: Adiponectin, Body Mass Index, Liver Function Tests, Mendelian
Randomization Analysis, Genetic Risk Score
1I. Introduction
1. Study Background
The obesity epidemic has been a major health problem, regardless of a nation’s economic 
status or ethnicity. The incidence of obesity-related disorders or complications has also 
been rising proportionally. In the field of gastroenterology, nonalcoholic fatty liver 
disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are of particular concern due 
to their increased prevalence and potential to progress to liver fibrosis or advanced liver 
disease.1,2 It has long been recognized that obesity, type 2 diabetes, and hepatic steatosis
are closely related with insulin resistance as a critical factor involved in their common
pathophysiology; fatty liver disease is now considered a hepatic component of metabolic 
syndrome, or hepatic manifestation of insulin resistance.2-6
There are several laboratory tests for evaluating liver health or function. They include: 
liver enzyme assays such as aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), and lactate 
dehydrogenase (LDH); tests for liver synthetic function such as serum albumin level and 
prothrombin time (PT); and serum bilirubin level as a reflection of liver excretory 
function.7 Results from sensitive liver enzyme tests that indicate hepatocyte injury are 
generally used for assessing liver abnormality in clinical or research settings. AST and 
2ALT, two important serum aminotransferase or transaminase enzymes, are representative 
liver enzymes that are elevated because they are released in greater amounts into the 
bloodstream through the damaged liver cell membranes with increased permeability. The 
majority of AST is found in the liver, but also found in cardiac muscle, skeletal muscle, 
kidneys, brain, pancreas, lungs, white and red blood cells; in contrast, ALT 
predominantly exists in the liver (more than 98%). Therefore, the latter is considered as a 
more specific indicator of liver injury, rarely confused with changes from other organs.8
The association between obesity and hepatocyte injury, or liver disease, has been 
continuously suggested across a wide age spectrum.9-15 Along with the obesity, 
adiponectin, a hormone secreted by adipose tissue and known for having anti-lipogenic 
and anti-inflammatory effects, has been another issue regarding its potential role in 
hepatocyte protection against lipid accumulation, fibrosis, and cirrhosis in both human 
and animal livers.16-19 Because of these associations, adiponectin has been connected to
treatment of obesity-related metabolic diseases including liver disorders. It has been
proposed as the final or intermediate therapeutic target of such diseases, or as a 
monitoring target for treating fatty liver disease.16,17,19-21
Although this study first assesses serum aminotransferase levels to evaluate potential 
liver disease or hepatocyte injury, it is important to note that elevated aminotransferase
levels, though not serious, may also indicate other conditions. In addition to having been 
3widely used to check hepatic function in patients with metabolic syndrome,22-24 they have 
also been associated with metabolic syndrome risk and death, diabetes, and 
cardiovascular disease; they have also been used as a measure of overall health and 
mortality risk, including mortality from liver diseases.25-29 Hence, the studies involving 
liver enzymes as dependent variables may have further implications.
As mentioned above, there have been many studies on the relationship between obesity or 
adiponectin and abnormal liver function or liver diseases; however, all of them had 
limitations because they were observational studies. They suggested associations, but 
could not demonstrate causation. However, in recent decades, such obesity-related 
etiologies have become increasingly important along with the development of medical 
technology in treatment modalities for hepatitis virus and malignant tumors. Now it is 
needed to identify causal metabolic factors for liver cell damage or liver diseases, while
distinguishing them from intermediate outcomes of abnormal liver function or related 
alterations.
Mendelian randomization is a statistical analysis that applies the method of instrumental 
variable analysis to observational epidemiological study, using genetic information as an 
instrument.30 It is accepted as a method to account for the limitations of observational
studies and enables the establishment of causal relationships. It also allows for an 
assessment of pathogenetic and therapeutic implications derived from the study results.
42. Study Objectives
The purpose of this study is to investigate whether adiponectin and obesity are causally 
associated with abnormal aminotransferase levels by applying a Mendelian randomization
study design using the population-based Korean Cancer Prevention Study-II (KCPS-II) 
Biobank Cohort data.
The detailed objectives of this study were as follows:
1) To search for genetic variations regarding serum adiponectin level and body 
mass index (BMI) among people declared to be negative in both hepatitis B virus 
antigen and C virus antibody tests from the KCPS-II subcohort by performing a
genome-wide association study (GWAS) using a customized chip.
2) To test the hypothesis that adiponectin and obesity are causally associated with 
hepatocyte injury, which can be inferred from the results of serum 
aminotransferases assay ‒ it could be assessed by adopting discovered genetic 
variations or genetic risk scores as unconfounded surrogates for exposure 
variables, and performing a Mendelian randomization analysis in comparison to 
the results from conventional regression analysis.
5II. Materials and Methods
1. Study Population
The KCPS-II Biobank consisted of participants’ health examination data and blood 
samples obtained from multiple health promotion centers of hospitals located in Seoul 
and Gyeonggi province. Data collection started in April 2004 and the number of 
participating hospitals was gradually increased, having attained a constant contribution 
from 11 hospitals since 2006. More detailed descriptions about the original KCPS-II 
cohort design and characteristics have been previously published.31,32
Among the health examination participants from 2004 to 2013, the number of subjects 
who had provided informed consent for the study was 159,844. Within this population, 
there were 111,511 participants who satisfied all of following conditions: people who 
were 30 years or older at the time of examination, had no history of cancer, stroke, and 
cardiovascular disease, had no missing or extremely abnormal values for the essential
variables including fasting blood glucose, weight, height, BMI, waist circumference, 
HDL-cholesterol, AST, ALT, GGT, smoking status, and alcohol drinking status, and 
enrolled in the study before December 31, 2008. Then we randomly selected 5,000 
subjects (3,337 men and 1,663 women) among them for the final subcohort group.
6There were 3,839 participants who were negative for both hepatitis B virus antigen and 
hepatitis C virus antibody tests in the subcohort, and 3,817 of them had adequate genetic 
information that was obtained through various quality control methods for genotyping
(described below). Finally, we excluded 24 subjects with extremely high BMI (over 40
kg/m2) and liver enzyme levels (AST, ALT over 120 IU/L), resulting in 3,793 (2,483
males and 1,310 females) participants for the final study population (Figure 1).
7Figure 1. Flow chart describing the study population
82. Data Collection
Each participant was interviewed through a structured questionnaire to collect 
demographic and behavioral information such as age, sex, cigarette smoking, education, 
alcohol intake, and exercise status. Participants undertook a medical examination as well;
body weight and height were measured while participants were wearing light clothing, 
BMI was calculated as weight (kg) divided by the square of height (m2), and waist 
circumference was measured midway between the lower rib and iliac crest.
For the clinical chemistry assay, serum was separated from peripheral venous blood 
samples that were obtained from each participant after 12 hours of fasting and was stored 
at -70°C. Serum biomarkers, including liver enzymes such as AST, ALT, GGT, and LDH 
were measured using the Histachi-7600 analyzer (Hitachi Ltd., Tokyo, Japan). 
Adiponectin level was measured using an enzyme-linked immunosorbent assay (Mesdia 
Co. Ltd., Seoul, Korea). The intra-assay and interassay variances for adiponectin were 6.3% 
to 7.4% and 4.5% to 8.6%, respectively.31 Each measurement laboratory had internal and 
external quality control procedures as required by the Korean Association of Laboratory 
Quality Control.
93. Genotyping and quality control
Genotyping of DNA was performed with whole blood samples from the KCPS-II 
Biobank using the Korean Chip (K-CHIP) available through the K-CHIP consortium. A 
full description about DNA amplification and the genotyping process using the K-CHIP 
is provided in a previous report.32 For the last step in the genotyping process, SNPs were 
identified using the Genotyping Console™ Software (Affymetrix, Santa Clara, CA, USA). 
Of the 5,000 individuals who underwent genotyping, we first removed samples with a
gender mismatch, mutual blood relationship, or had poor genotype data quality such as 
low genotyping rate. As a result, we obtained a genotype dataset of 3,817 individuals 
among 3,839 participants who were free of hepatitis B or C viral infection. In performing 
a GWAS in the final study group (N=3,793), individuals and markers with low call rate 
(< 0.95), deviation from Hardy-Weinberg equilibrium (p < 1.0ⅹ10-4), or significantly 
low minor allele frequency (< 0.01) were also excluded. Therefore 3,780 individuals and
600,712 SNPs were used for a genome-wide association analysis, for the purpose of 
selecting SNPs highly associated with BMI or adiponectin in our study population.
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4. Mendelian randomization analysis
As one of the methodologies that determine causation and resolve noncomparability 
problems (commonly referred to as confounding) in observational epidemiologic studies, 
a counterfactual (or potential outcome) model approach has been discussed in great detail 
for a decade.33-36 In this model, based on contrary-to-fact conditionals, or hypothetical 
situations, the causality of risk factors on outcomes can be identified by comparing the 
exposed individual's outcome to the expected outcome when the same individual is not 
exposed to a risk; this means all conditions except the exposure to a risk are completely 
identical in these two settings.
Instrumental variable (IV), a method introduced from econometrics, has been used for 
making counterfactual causal inference in epidemiological studies.37,38 The IV, denoted 
by Z below, was the fourth variable satisfying the following conditions: (1) Z is 
associated with the exposure of interest X, (2) Z is independent of the confounding 
factors U (measured and unmeasured) that confound the exposure X ‒ outcome Y 
relationship, (3) Z is independent of Y given X and all confounders U (measured and 
unmeasured) of the X ‒ Y association (i.e., ‘Z affects outcome Y only through exposure 
X’ or ‘Z has no direct effect on Y’). By using such IV that has no relationship with any 
confounders existing in the study, causal inference between the exposure and outcome 
became possible. This approach enables control over various confounding factors by 
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adopting the IV as a surrogate exposure which acts on the outcome only through the 
exposure variable.
Based on this concept, Mendelian randomization was presented as an approach using 
genetic markers as the IV.39-41 It was a method that focused on the law of random 
assortment (Mendel’s second law), which states the inheritance of any trait is independent 
of the inheritance of other traits, and applied it to the epidemiological setting. In other 
words, since chromosomes and genes are randomly assigned during reproduction, genetic 
polymorphism that reflects exposure can be used as the IV independent from possible 
confounders with the final outcome variable. In this regard, genetic variables to be used 
must meet the same basic assumptions of the IV as well. Lawlor et al. 30 summarized the 
three assumptions that the Mendelian randomization approach presupposes as follows:
(1) The genotype is robustly associated with the modifiable (non-genetic) exposure of 
interest. 
(2) The genotype is not associated with confounding factors that bias conventional 
epidemiological associations between modifiable risk factors and outcomes. 
(3) The genotype is related to the outcome only via its association with the modifiable 
exposure (the assumption also known as ‘exclusion restriction’).
This Mendelian randomization method that uses a genetic variant for epidemiological
causal inference, although there are some limitations that will be discussed later in the 
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discussion section, also can overcome the reverse causation problem and reduce the 
inevitable confound of a conventional observational epidemiologic study. In the present 
work, we estimated the potential causal association between the exposure of interest (X; 
in this study, serum adiponectin level and BMI) and outcome (Y; in this study, abnormal 
liver enzyme levels) by using the genetic traits (G; in this study, each single SNP or 
genetic risk scores) as an instrumental variable (Figure 2).
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(A) (B)
Figure 2. Causal structures encoding the genetic variants as an instrumental variable to estimate the effect of 
(A) adiponectin and (B) body mass index (BMI) on the elevation in liver enzyme levels
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5. IV selection and constructing genetic risk scores
We performed a GWAS with each explanatory variable, serum adiponectin level and 
BMI. Of the top 20 SNPs that were highly associated with adiponectin levels or BMI, we 
selected the single representative SNP in each trait (as the first IV) based on p-value and 
coefficient results of linear regression, together with congruity between newly gained and 
previously reported lists.
SNPs for constructing genetic risk score (GRS) were sorted out by removing the other 
SNPs in linkage disequilibrium (LD) with D’ greater than 0.80. A weighted GRS was 
developed (as the second IV, indicated as GRS1 in the later sections) using these 
mutually independent SNPs, with each variant’s effect size according to the number of 
risk alleles. For each genotype result of selected SNPs, participants received an allele 
score of 0, 1, or 2 for carrying zero (wild-type homozygous), one (heterozygous), or two 
(homozygous for the risk allele) adiponectin-decreasing or BMI-increasing risk alleles, 
respectively. The GRS was then calculated by adding scores of all selected SNPs, 
weighted by the respective coefficient for one or two allele change estimated for the 
corresponding SNP.
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6. Definitions of outcomes
The outcome variable for this research was serum aminotransferase level, defined in two 
ways. The first one was a binary outcome, which included elevated and normal 
aminotransferase levels. A problematic outcome was considered as a group of people who 
had AST ≥ 40 IU/L or ALT ≥ 40 IU/L. The second was a continuous level outcome of 
serum ALT, a highly specific liver enzyme recognized as a more appropriate biomarker 
for liver injury.
Participants who demonstrated extremely high AST or ALT levels that exceeded three 
times the upper normal limit (>120 IU/L) were excluded from the study, because it was
highly suggestive of liver disease with distinct etiology other than or independent of 
obesity.
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7. Sensitivity analyses
To increase reliability of the study results, another GRS was generated (as the third IV, 
indicated as GRS2 in the later sections) using candidate SNPs for each trait, adiponectin
level and BMI. Among diverse loci which have been revealed to affect adiponectin level, 
ADIPOQ variants were selected as the candidate SNPs for constructing adiponectin GRS. 
Similarly, SNPs in FTO or MC4R genes were chosen for the BMI GRS. SNPs were 
selected according to the order of their significance level, and all other interrelated SNPs 
with LD were excluded. Methods for GRS calculation were similarly conducted as those 
described above. 
Another sensitivity analysis was conducted after excluding heavy drinkers because they 
could have elevated liver enzyme levels due to exogenous effect. Among 3,531 
participants who had the information of alcohol drinking amount, those with an average 
intake of more than 50g per day (n=263) were excluded. In the analysis, the amount of 
alcohol drinking was used as a covariate for adjustment. 
Potential pleiotropy and genetic confounders were also assessed. First, although limitedly,
extra route from genetic instruments (G) to the outcome variable (Y), other than exposure 
variable (X) itself, was evaluated; it was done graphically by checking if any alteration in 
effect on outcome estimates (Y) was observed within the independent genetic instruments 
(G) of respectively different effect sizes for their related phenotype. Second, reciprocal 
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relationships between exposure and outcome variables were explored using genetic traits 
determining the liver enzyme levels; in order to assess further existence of genetic 
variants that were related to both exposure (X) and outcome (Y) variables. The LD 
relationships between SNPs determining liver enzyme levels (Y) and SNPs used as 
genetic instruments (G) of adiponectin level and BMI (X) were also evaluated. Third, 
SNPs used in the IV of adiponectin levels or BMI (X), respectively, were tested if they 
had any LD association with each other in the same chromosome.
8. Statistical analysis
In order to assess general characteristics of study participants, descriptive analysis was 
conducted; means and standard deviations (SD) were calculated for continuous variables, 
and frequencies and relative proportions were estimated for categorical variables. All of 
measured variables that showed skewed distribution were log-transformed for the 
statistical tests and regression analyses. 
In performing GWAS, associations of each SNP with serum adiponectin level and BMI 
were tested by linear regression under an additive genetic model adjusting for age and sex.
It was performed using PLINK 1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/).
Haploview version 4.1 (http://www.broad.mit.edu/mpg/haploview/) was used to generate 
Manhattan plots and evaluate LD structures. With an adjustment for age and sex, per 
18
allele changes and effects of different genotypes on adiponectin level and BMI were
calculated by ordinary least square (OLS) regression, using SAS version 9.4 (SAS
Institute Inc., Cary, NC, USA). Evaluation for the liver enzyme level-related SNPs were 
conducted with identical methods and tools with additional adjusting for alcohol 
consumption status. 
Tests for the differences in variables among the three genotypes for each representative 
SNP were performed by ANOVA and chi-square tests. In case of continuous variables, 
associations between these potential confounders and GRS were evaluated through 
correlation analysis. For categorical variables, nonparametric test such as Wilcoxon rank 
two-sample or Kruskal-Wallis test was used for adiponectin GRS, and chi-square test was 
used in BMI GRS. To evaluate observed estimates between an exposure of interest and 
outcomes, OLS regression or conventional multivariate logistic regression method was 
used. 
Mendelian randomization analysis was performed with two different methods: Wald 
estimator and two-stage least squares method. The first common step in both methods 
was to assess the association between genetic traits and exposure variables. Linear 
regression was used to measure the strength of the association between genetic variants or 
GRS and the exposures of interest (X), under the assumption of an additive genetic model. 
The significance of genetic variables was estimated by F statistics, and the final 
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regression coefficients of the genetic IV (G) on the exposure variables (X) is expressed as 
     in the description below. 
Using this result, we assessed the causal effect of X on binary outcome Y using the Wald 
estimator approach. The final estimates, or the log odds ratios of abnormal AST or ALT
per unit decrease in adiponectin and increase in BMI, respectively, were calculated using
a Wald/ratio estimator 42:
	     =
log	(    )
    
The confidence interval for this ratio estimate was obtained using the delta method, which 
is also termed as a Taylor series expansion.40
We also assessed the causal effect of X on continuous outcome Y using the two-stage 
least squares (2SLS) approach. It consists of two stages: (1) A conventional least-squares 
regression between the genetic IV (G) and the exposure (X) variables (2) Subsequent 
least-squares regression of the outcome Y on the predicted value of exposure (X), which 
could be derived from the first stage regression and saved as  .  Such an approach can be 
simplified as follows:
    =    +      +     +    (2)
    =     =    +     +      +	   (1)
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Here,     is the outcome variable (Y);    , the endogenous regressor, is the predicted 
exposure (X) calculated from the results of the first regression (   would be substituted 
with      when    is a genetic IV);    and    represent the exogenous regressors, 
collectively referred as the instruments;    and    are error terms for the   th 
observation.
To examine whether the genetically predicted exposure variables (   ) were endogenous
in reality, we performed a Durbin and Wu-Hausman test that assesses covariance between 
exposure variable of interest and residuals. These Mendelian randomization analyses 
were performed with the STATA package ivregress, using STATA software version 12
(Stata Corp. LP, College Station, TX, USA). All statistical tests were two-sided and p
<0.05 was considered statistically significant.
9. Ethics statement
This study was approved by an Institutional Review Board of Graduate school of Public 
Health, Yonsei University [IRB Number: 2-1040939-AB-N-01-2016-111].
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III. Results
1. General characteristics of study population
A total of 3,793 participants (2,483 men and 1,310 women) were included in the analysis 
from the KCPS-II Biobank subcohort, with the measurement of adiponectin and BMI 
levels as well as the genotyping of relevant genomes. General characteristics of the study 
participants are summarized in Table 1. Participants were primarily early middle-aged, 
and the distribution of key variables except age showed statistically significant difference 
between men and women. A large proportion of non-drinkers and non-smokers were 
women, whereas the most of alcohol drinkers and smokers were men.
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Table 1. General characteristics of the study population, by sex
Total (N=3,793) Men (N=2,483) Women (N=1,310)
Mean/N (SD,%) Mean/N (SD,%) Mean/N (SD,%)
Age (years) 42.55 (8.8) 42.47 (8.6) 42.69 (9.3)
BMI (kg/m2) 23.73 (3.0) 24.46 (2.7) 22.34 (3.1)
Waist circumference (cm) 81.16 (9.0) 84.77 (7.2) 74.33 (8.1)
Adiponectin (μg/mL) 7.13 (4.1) 5.93 (3.1) 9.41 (4.8)
Bilirubin (mg/mL) 0.92 (0.4) 0.99 (0.4) 0.78 (0.3)
Albumin (g/mL) 4.57 (0.2) 4.62 (0.2) 4.50 (0.2)
Education (years) 14.48 (3.0) 15.18 (2.6) 13.44 (3.3)
Drinking No 890 (23.5) 261 (10.5) 629 (48.0)
Yes 2903 (76.5) 2222 (89.5) 681 (52.0)
Smoking No 1853 (48.9) 647 (26.1) 1206 (92.1)
Past 767 (20.2) 706 (28.4) 61 (4.7)
Current 1173 (30.9) 1130 (45.5) 43 (3.3)
Exercise No 2297 (62.9) 1617 (67.0) 680 (54.8)
Yes 1357 (37.1) 797 (33.0) 560 (45.2)
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2. SNPs associated with exposure variables
A genome-wide association with adiponectin level and BMI in 3,793 individuals revealed
a number of genetic polymorphisms affecting these intermediate phenotypes. Tables 2 
and 3 show the list of 20 SNPs relevant to serum adiponectin level and BMI, respectively, 
with the lowest p-values in the study participants. Manhattan plots of these genome-wide 
analyses are provided in Appendix B1. 
Most of the highly significant polymorphisms for adiponectin level belonged to 
chromosome 16, which includes the CDH13 gene, and majority of those SNPs were 
located on that gene or were in LD with SNPs on that gene. Similarly, but less markedly, 
the highly significant SNPs associated with BMI were relatively concentrated on 
chromosome 11, which includes the BDNF gene. Most of those SNPs were related to
each other as in LD. Finally, it was rs4783244 and rs2030323 variants that were selected 
as a single SNP instrumental variable for Mendelian randomization analysis, respectively. 
Weighted GRSs were also created using 7 representative SNPs for adiponectin level and 
13 representative SNPs for body mass index.
Most of SNPs with low p-values that were located in or nearby CDH13 gene revealed
high significance for adiponectin levels (p = 9.30ⅹ10-44 to 4.24ⅹ10-16), whereas the 
24
significance of SNPs located in or nearby BDNF gene were not much strong (p = 
3.14ⅹ10-7 to 1.02ⅹ10-5) for their relationships with BMI.
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Table 2. Top 20 SNPs strongly relevant to serum adiponectin level among the study population, without hepatitis 
B or C viral infection
Chr SNP
Risk 
allele
Other 
allele 
RAF
Nearest
gene
per allele change 1 Risk allele 2 Risk alleles
GRS1
beta SE beta SE beta SE
16 rs16957889 G A 0.300 CDH13 -0.1796 (0.0139) -0.1620 (0.0190) -0.3820 (0.0326)
16 rs4783244 T G 0.301 CDH13 -0.1805 (0.0140) -0.1658 (0.0191) -0.3802 (0.0327)
16 rs12596316 G A 0.306 CDH13 -0.1721 (0.0139) -0.1570 (0.0191) -0.3630 (0.0322)
16 rs3852724 A C 0.543 CDH13 -0.1072 (0.0131) -0.0934 (0.0241) -0.2121 (0.0264) *
16 rs7193788 G A 0.453 CDH13 -0.1057 (0.0133) -0.0764 (0.0213) -0.2176 (0.0267) *
16 rs16957913 C T 0.221 CDH13 -0.1182 (0.0157) -0.1101 (0.0196) -0.2570 (0.0435) *
3 rs864265 T G 0.091 ADIPOQ -0.1494 (0.0229) -0.1609 (0.0246) -0.1640 (0.1144) *
3 rs74577862 A G 0.019 ADIPOQ -0.3153 (0.0472) -0.3128 (0.0493) -0.6859 (0.3226)
3 rs2036373 G T 0.037 ADIPOQ -0.2149 (0.0355) -0.2149 (0.0355) NA *
16 rs3865183 C T 0.584 CDH13 -0.0744 (0.0133) -0.0512 (0.0261) -0.1417 (0.0275)
16 rs3852728 G A 0.837 CDH13 -0.0863 (0.0176) -0.0991 (0.0580) -0.1828 (0.0563)
16 rs17244777 C A 0.228 CDH13 -0.0639 (0.0157) -0.0594 (0.0195) -0.1395 (0.0437) *
8 rs28455997 C T 0.064 CSMD1 -0.1130 (0.0267) -0.1106 (0.0285) -0.2588 (0.1451) *
16 rs8062678 T G 0.829 CDH13 -0.0719 (0.0174) -0.0911 (0.0565) -0.1589 (0.0549)
8 rs10091165 A C 0.066 CSMD1 -0.1053 (0.0261) -0.1059 (0.0283) -0.2038 (0.1292)
8 rs73185530 A G 0.065 CSMD1 -0.1041 (0.0264) -0.1024 (0.0283) -0.2286 (0.1364)
8 rs17079690 C G 0.073 CSMD1 -0.1041 (0.0249) -0.0813 (0.0270) -0.4456 (0.1199)
8 rs74350387 C A 0.067 CSMD1 -0.1063 (0.0261) -0.1049 (0.0281) -0.2293 (0.1326)
8 rs117585453 A G 0.066 CSMD1 -0.1035 (0.0261) -0.1017 (0.0281) -0.2285 (0.1326)
16 rs79003691 T C 0.035 CDH13 -0.1620 (0.0351) -0.1508 (0.0374) -0.4877 (0.1984)
Adjusted for age and sex
SNP, single nucleotide polymorphism; RAF, Risk allele frequency
* SNPs used for GRS1: selected SNPs after excluding highly interrelated SNPs with linkage disequilibrium (LD) from the original top 20 SNPs
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Table 3. Top 20 SNPs strongly relevant to body mass index among the study population, without hepatitis B or C 
viral infection
Chr SNP
Risk 
allele
Other 
allele 
RAF
Nearest
gene
per allele change 1 Risk allele 2 Risk alleles
GRS1
beta SE beta SE beta SE
11 rs2030323 C A 0.545 BDNF 0.3068 (0.0700) 0.2987 (0.1290) 0.6123 (0.1413) *
11 rs6265 C T 0.538 BDNF 0.2954 (0.0699) 0.2807 (0.1272) 0.5886 (0.1407)
11 rs11230563 T C 0.197 CD6 0.3899 (0.0874) 0.3758 (0.1058) 0.8254 (0.2607) *
11 rs11030084 C T 0.550 BDNF-AS 0.2700 (0.0699) 0.1043 (0.1299) 0.5084 (0.1413)
8 rs2890502 T C 0.928 EYA1 0.5911 (0.1332) 0.2098 (0.6418) 0.8357 (0.6296) *
11 rs4074134 C T 0.546 BDNF-AS 0.2616 (0.0699) 0.1139 (0.1290) 0.4972 (0.1411)
11 rs10501087 T C 0.538 BDNF-AS 0.2585 (0.0698) 0.1685 (0.1274) 0.5034 (0.1406)
8 rs16875189 T C 0.088 ABRA 0.4501 (0.1233) 0.4769 (0.1329) 0.6024 (0.6054) *
5 rs56718608 A C 0.082 C5orf66 0.5706 (0.1255) 0.5648 (0.1374) 1.1944 (0.5708) *
9 rs10858232 A G 0.166 LHX3 0.3762 (0.0929) 0.4402 (0.1099) 0.4963 (0.2997) *
18 rs17782313 C T 0.248 MC4R 0.3354 (0.0792) 0.3535 (0.1038) 0.6373 (0.2016) *
18 rs571312 A C 0.247 MC4R 0.3317 (0.0795) 0.3635 (0.1036) 0.6023 (0.2038)
2 rs79091937 G A 0.889 SEPT2 0.4067 (0.1110) 0.6409 (0.4626) 1.0191 (0.4524) *
14 rs139904021 C T 0.978 PSMA3 1.0828 (0.2486) reference 1.0828 (0.2486) *
4 rs6844085 T G 0.941 FIP1L1 0.5186 (0.1502) 0.5320 (0.8830) 1.0498 (0.8717) *
18 rs10871777 G A 0.248 MC4R 0.3300 (0.0792) 0.3567 (0.1039) 0.6106 (0.2009)
8 rs6986205 G A 0.011 OXR1 1.3629 (0.3425) 1.3629 (0.3425) NA *
7 rs140874255 C T 0.982 ZNF890P 1.1407 (0.2698) reference 1.1407 (0.2698) *
7 rs80171753 T C 0.979 ZNRF2 1.0589 (0.2558) reference 1.0589 (0.2558) *
18 rs1350341 A G 0.286 MC4R 0.3272 (0.0766) 0.3401 (0.1028) 0.6352 (0.1846)
Adjusted for age and sex
SNP, single nucleotide polymorphism; RAF, Risk allele frequency
* SNPs used for GRS1: selected SNPs after excluding highly interrelated SNPs with linkage disequilibrium (LD) from the original top 20 SNPs
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Candidate SNPs of the target genes selected by GWAS analysis are listed in Tables 4 and 
5. They showed relatively weak significances in association with their phenotypes. Hence,
the entire independent SNPs detected for each trait were collectively used to construct 
GRS. A total of 6 SNPs in ADIPOQ gene, 8 SNPs in FTO gene, and 5 SNPs in MC4R
genes were finally selected.
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Table 4. A list of 6 SNPs for construction of candidate genetic risk score (GRS2) for adiponectin level
Chr SNP
Risk 
allele
Other 
allele 
RAF Gene
per allele change 1 Risk allele 2 Risk alleles
beta SE beta SE beta SE
3 rs864265 T G 0.091 ADIPOQ -0.1494 (0.0229) -0.1609 (0.0246) -0.1640 (0.1144)
3 rs2036373 G T 0.037 ADIPOQ -0.2149 (0.0355) -0.2149 (0.0355) NA
3 rs2117986 C T 0.269 ADIPOQ -0.0662 (0.0147) -0.0719 (0.0194) -0.1225 (0.0366)
3 rs117147558 T C 0.077 ADIPOQ -0.0286 (0.0246) -0.0261 (0.0265) -0.0862 (0.1231)
3 rs17366568 A G 0.022 ADIPOQ -0.0868 (0.0452) -0.0868 (0.0452) NA
3 rs1501299 T G 0.303 ADIPOQ -0.0115 (0.0142) -0.0176 (0.0195) -0.0154 (0.0329)
Adjusted for age and sex
SNP, single nucleotide polymorphism; RAF, Risk allele frequency
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Table 5. A list of 13 SNPs for construction of candidate genetic risk score (GRS2) for body mass index
Chr SNP
Risk 
allele
Other 
allele 
RAF Gene
per allele change 1 Risk allele 2 Risk alleles
beta SE beta SE beta SE
16 rs9302654 T C 0.132 FTO 0.3459 (0.1033) 0.2973 (0.1158) 1.0132 (0.4034)
16 rs116978290 G A 0.960 FTO 0.5693 (0.1890) 1.8511 (1.7520) 2.3906 (1.7428)
16 rs879679 C T 0.239 FTO 0.2304 (0.0807) 0.2188 (0.1038) 0.4851 (0.2112)
16 rs76368010 C T 0.923 FTO 0.1964 (0.1303) 0.8078 (0.6564) 0.9541 (0.6456)
16 rs12446738 A C 0.013 FTO 0.8015 (0.3134) 0.8015 (0.3134) NA
16 rs2058908 C T 0.700 FTO 0.1411 (0.0758) 0.2222 (0.1813) 0.3288 (0.1788)
16 rs117659448 C T 0.024 FTO 0.4467 (0.2285) 0.4467 (0.2285) NA
16 rs7185479 C A 0.157 FTO 0.1765 (0.0953) 0.1457 (0.1114) 0.4901 (0.3199)
18 rs17782313 C T 0.248 MC4R 0.3354 (0.0792) 0.3535 (0.1038) 0.6373 (0.2016)
18 rs55963627 T G 0.042 MC4R 0.2097 (0.1722) 0.1588 (0.1811) 1.3378 (1.0679)
18 rs187398163 A G 0.984 MC4R 0.4413 (0.2933) reference 0.4413 (0.2933)
18 rs2229616 C T 0.976 MC4R 0.2441 (0.2324) reference 0.2441 (0.2324)
18 rs7239577 T C 0.031 MC4R 0.2295 (0.2031) 0.2295 (0.2031) NA
Adjusted for age and sex
SNP, single nucleotide polymorphism; RAF, Risk allele frequency
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3. Associations of intermediate phenotype and potential confounders 
with genetic variables
Genotype frequencies of adiponectin-related rs4783244 for genotypes GG, TG, and TT 
were 48.4%, 42.1%, and 9.0%, respectively, in the study population. Mean adiponectin 
level was the lowest in rs4783244*TT carriers (5.42 ± 3.23 mg/dL, n=343), and increased 
gradually as the number of risk allele (T) declined. Genotype frequencies of BMI-related 
rs2030323 for genotypes CC, AC, and AA were 29.5%, 50.0%, and 20.2%, respectively. 
Mean BMI was the highest in rs2030323 homozygous carriers of risk allele (CC) with 
mean BMI of 24.01 kg/m2 (SD 3.01 kg/m2, n=1,119), and decreased as C allele declined
(Tables 6 and 7). Figure 3 describes a distribution of GRS1 for adiponectin levels and 
BMI which consist of de novo SNPs marked with corresponding mean levels of 
adiponectin and BMI, respectively. 
To assess the second assumption of Mendelian randomization analysis described in the 
methods section, we tested whether single SNPs or GRSs used as the IV were associated 
with potential confounders (Tables 6 and 7). No significant differences across genotype 
groups and GRS were shown regarding age, sex, drinking status, and exercise status, for 
both intermediate phenotype variables of adiponectin and BMI. Genetic traits for 
adiponectin level had no association with BMI, waist circumference, and education level; 
however they showed significant association with smoking status among the genotype 
subgroups. Genetic traits for BMI were significantly associated with waist circumference, 
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adiponectin level (in case of GRS), and education level (among the genotype subgroups), 
but had no relationship with smoking status.
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Table 6. Associations of potential confounders with CDH13 polymorphism at rs4783244 for adiponectin level and genetic risk 
scores among the study population
rs4783244 GG (N=1,837) TG (N=1,597) TT (N=343) GRS1a GRS2b
Variables Mean/N(SD,%) Mean/N (SD,%) Mean/N (SD,%) p r/mean (SD) p r/mean (SD) p
Age 42.39 (8.74) 42.58 (8.93) 43.22 (8.39) 0.266 0.027 0.105 0.001 0.973 
Sex Men 1202 (48.66) 1028 (41.62) 240 (9.72) 4.56 (3.6) 1.12 (1.3)
Women 635 (48.58) 569 (43.53) 103 (7.88) 0.141 4.57 (3.5) 0.608 d 1.07 (1.3) 0.055 d
BMI 23.65 (3.00) 23.8 (3.02) 23.79 (3.10) 0.335 0.008 0.613 0.012 0.448 
Waist circumference 80.87 (8.92) 81.37 (9.19) 81.69 (8.98) 0.139 0.008 0.619 0.0002 0.989 
Adiponectinc 7.85 (4.34) 6.66 (3.76) 5.42 (3.23) <0.001 c -0.208 c <0.001 c -0.143 c <0.001 c
Education 14.48 (2.95) 14.44 (3.07) 14.71 (2.71) 0.613 0.013 0.614 0.004 0.871 
Drinking No 418 (47.13) 385 (43.40) 84 (9.47) 4.68 (3.6) 1.09 (1.3)
Yes 1419 (49.10) 1212 (41.94) 259 (8.96) 0.582 4.52 (3.6) 0.143 d 1.10 (1.3) 0.331 d
Smoking No 876 (47.38) 813 (43.97) 160 (8.65) 4.62 (3.6) 1.11 (1.3)
Past 365 (47.96) 305 (40.08) 91 (11.96) 4.66 (3.7) 1.14 (1.3)
Current 596 (51.07) 479 (41.05) 92 (7.88) 0.008 4.39 (3.5) 0.135 d 1.05 (1.2) 0.560 d
Exercise No 1082 (47.33) 982 (42.96) 222 (9.71) 4.64 (3.6) 1.11 (1.3)
Yes 683 (50.52) 559 (41.35) 110 (8.14) 0.100 4.42 (3.5) 0.086 d 1.09 (1.3) 0.948 d
a GRS1: Using de novo SNPs obtained from GWAS       b GRS2: Using candidate SNPs from the target gene (ADIPOQ)
c Tests for difference performed with log-transformed value d Tests for difference conducted by nonparametric methods
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Table 7. Associations of potential confounders with BDNF polymorphism at rs2030323 for body mass index and genetic risk 
scores among the study population
rs2030323 CC (N=1,119) AC (N=1,896) AA (N=765) GRS1a GRS2b
Variables Mean/N (SD,%) Mean/N (SD,%) Mean/N (SD,%) p r/mean (SD) p r/mean (SD) p
Age 42.82 (8.88) 42.37 (8.72) 42.59 (8.95) 0.396 0.017 0.296 -0.001 0.947 
Sex Men 712 (28.78) 1256 (50.77) 506 (20.45) 9.56 (1.3) 8.00 (1.1)
Women 407 (31.16) 640 (49.00) 259 (19.83) 0.311 9.60 (1.3) 0.455 7.94 (1.1) 0.177 
BMI 24.01 (3.01) 23.70 (3.01) 23.4 (3.03) <0.001 0.216 <0.001 0.108 <0.001
Waist circumference 81.6 (8.98) 81.18 (8.94) 80.53 (9.37) 0.039 0.161 <0.001 0.084 <0.001
Adiponectinc 7.06 (4.24) 7.12 (4.00) 7.23 (4.04) 0.510 c -0.038 c 0.021 c -0.015 c 0.377 c
Education 14.23 (3.13) 14.73 (2.77) 14.21 (3.22) 0.003 -0.032 0.197 0.007 0.794 
Drinking No 272 (30.63) 418 (47.07) 198 (22.30) 9.56 (1.3) 7.95 (1.1)
Yes 847 (29.29) 1478 (51.11) 567 (19.61) 0.080 9.58 (1.3) 0.690 7.99 (1.1) 0.330 
Smoking No 553 (29.96) 931 (50.43) 362 (19.61) 9.57 (1.3) 7.96 (1.1)
Past 222 (28.98) 386 (50.39) 158 (20.63) 9.54 (1.3) 8.02 (1.1)
Current 344 (29.45) 579 (49.57) 245 (20.98) 0.905 9.61 (1.3) 0.553 7.98 (1.1) 0.389 
Exercise No 675 (29.50) 1144 (50.00) 469 (20.50) 9.58 (1.3) 7.99 (1.1)
Yes 400 (29.56) 691 (51.07) 262 (19.36) 0.691 9.56 (1.3) 0.678 7.95 (1.1) 0.226 
a GRS1: Using de novo SNPs obtained from GWAS   b GRS2: Using candidate SNPs from the target genes (FTO and MC4R)
c Tests for difference performed with log-transformed value 
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(A)
(B)
Figure 3. (A) Distribution of weighted GRS for adiponectin level and corresponding 
mean adiponectin levels; (B) Distribution of weighted GRS for body mass index and 
corresponding mean body mass index
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4. Results of conventional regression and Mendelian randomization
analyses
Using the highly associated SNPs and GRSs from de novo SNPs, we conducted 
Mendelian randomization analysis to investigate whether adiponectin level and BMI
cause elevation of liver enzymes; we compared these results to the results from
conventional observational analyses (Tables 8-11). The first-stage F-statistics for the 
association between genetic traits and adiponectin levels or BMI were high enough to 
perform the analyses. 
For the analyses regarding adiponectin levels, it seemed to significantly decrease both the 
risk of elevation in liver aminotransferase (AST or ALT) levels (Table 8 and Figure 4) 
and log-transformed ALT level (Table 9), in conventional regression analyses. However, 
these relationships were not significant in Mendelian randomization analysis using the IV 
method, with any kind of genetic IV being used (Tables 8, 9 and Figure 4).
As for BMI, the results of conventional regression analyses regarding liver enzyme levels
were also significant, for both binary (Table 10 and Figure 5) and continuous (Table 11) 
outcomes. With Mendelian randomization using GRS1, these positive associations 
maintained the significance for the binary outcome (OR=1.36 with 95% CI from 1.16 to 
1.59, adjusted for age and sex) and the continuous outcome (β = 0.051 with p<0.001,
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adjusted for age and sex), implying that a causal relationship between BMI and the 
elevation in liver enzyme levels was reasonable (Tables 10, 11 and Figure 5).
Durbin-Wu–Hausman endogeneity test for adiponectin and BMI levels, respectively,
revealed p-values of clear or borderline significance (results not shown) to reject the null 
hypothesis (H0: instrumented regressors are in fact exogenous), thereby supporting the 
use of Mendelian randomization or IV method.
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Table 8. Association between adiponectin and abnormal liver enzyme level§, among subjects without hepatitis B or C viral infection
Explanatory
variables
Outcome
variable
Instrumental
variable
Change in 
log-transformed adiponectin 
per increase of one risk allele or 
one unit of GRS
Observational 
multivariate 
logistic regression 
analysis
Mendelian 
randomization 
analysis
β SE F R2 p OR CI p OR CI
Adiponectinc
elevated 
serum
AST or ALT
1 SNP
(rs4783244)
Model 1 -0.180 0.014 167 0.043 <.001 0.36 (0.30-0.43) <.001 1.10 (0.50-2.45)
Model 2 -0.177 0.013 288 0.189 <.001 0.48 (0.40-0.58) <.001 1.17 (0.51-2.68)
Model 3 -0.176 0.013 119 0.189 <.001 0.48 (0.40-0.58) <.001 1.19 (0.51-2.78)
GRS1a
Model 1 -0.033 0.003 162 0.043 <.001 0.36 (0.30-0.43) <.001 0.91 (0.41-2.03)
Model 2 -0.033 0.002 285 0.191 <.001 0.48 (0.40-0.58) <.001 0.86 (0.38-1.93)
Model 3 -0.033 0.002 118 0.191 <.001 0.48 (0.40-0.58) <.001 0.86 (0.38-1.96)
GRS2b
(ADIPOQ)
Model 1 -0.063 0.007 75.8 0.020 <.001 0.36 (0.30-0.43) <.001 0.73 (0.23-2.33)
Model 2 -0.060 0.007 243 0.167 <.001 0.48 (0.40-0.58) <.001 0.82 (0.23-2.86)
Model 3 -0.060 0.007 101 0.168 <.001 0.48 (0.40-0.58) <.001 0.84 (0.23-3.00)
a GRS1: Using de novo 7 SNPs obtained from GWAS    b GRS2: Using 6 candidate SNPs from the target gene (ADIPOQ)
c Log-transformed 
§ Binary outcome defined as serum aminotransferase (AST; Aspartate aminotransferase, or ALT; Alanine transaminase) level ≥ 40IU/L
Model 1: Crude model 
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, smoking status, alcohol drinking, and exercise status  
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Table 9. Association between adiponectin and serum ALT§ level, among subjects without hepatitis B or C viral infection
Explanatory
variables
Outcome
variable
Instrumental
variable
Change in 
log-transformed adiponectin 
per increase of one risk allele or 
one unit of GRS
Observational 
multivariate 
linear regression 
analysis
Mendelian 
randomization 
analysis
β SE F R2 p β SE p βIV SE p
Adiponectinc
serum 
ALT levelc
1 SNP
(rs4783244)
Model 1 -0.180 0.014 167 0.043 <.001 -0.292 0.015 <.001 -0.038 0.073 0.609 
Model 2 -0.177 0.013 288 0.189 <.001 -0.139 0.015 <.001 -0.009 0.067 0.892 
Model 3 -0.176 0.013 119 0.189 <.001 -0.138 0.015 <.001 -0.001 0.069 0.990 
GRS1a
Model 1 -0.033 0.003 162 0.043 <.001 -0.292 0.015 <.001 -0.019 0.075 0.798 
Model 2 -0.033 0.002 285 0.191 <.001 -0.139 0.015 <.001 -0.028 0.066 0.665 
Model 3 -0.033 0.002 118 0.191 <.001 -0.138 0.015 <.001 -0.028 0.068 0.677 
GRS2b
(ADIPOQ)
Model 1 -0.063 0.007 75.8 0.020 <.001 -0.292 0.015 <.001 -0.051 0.114 0.656 
Model 2 -0.060 0.007 243 0.167 <.001 -0.139 0.015 <.001 0.002 0.106 0.986 
Model 3 -0.060 0.007 101 0.168 <.001 -0.138 0.015 <.001 -0.010 0.108 0.925 
a GRS1: Using de novo 7 SNPs obtained from GWAS    b GRS2: Using 6 candidate SNPs from the target gene (ADIPOQ)
c Log-transformed          § ALT, Alanine transaminase (continuous outcome)
Model 1: Crude model 
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, smoking status, alcohol drinking, and exercise status  
39
Figure 4. Mendelian randomization of serum adiponectin level and elevated serum 
aminotransferase levels (AST, Aspartate aminotransferase; ALT, Alanine transaminase)
Figure 5. Mendelian randomization of body mass index and elevated serum 
aminotransferase levels (AST, Aspartate aminotransferase; ALT, Alanine transaminase)
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Table 10. Association between body mass index and abnormal liver enzyme level§, among subjects without hepatitis B or C 
viral infection
Explanatory
variables
Outcome
variable
Instrumental
variable
Change in body mass index 
per increase of one risk allele or 
one unit of GRS
Observational 
multivariate 
logistic regression 
analysis
Mendelian 
randomization 
analysis
β SE F R2 p OR CI p OR CI
BMI
elevated 
serum
AST or ALT
1 SNP
(rs2030323)
Model 1 0.307 0.070 19.2 0.005 <.001 1.41 (1.36-1.47) <.001 1.12 (0.72-1.73)
Model 2 0.330 0.065 198 0.136 <.001 1.39 (1.33-1.44) <.001 1.19 (0.78-1.81)
Model 3 0.313 0.066 88.3 0.144 <.001 1.40 (1.34-1.45) <.001 1.18 (0.85-1.63)
GRS1a
Model 1 0.502 0.037 182 0.046 <.001 1.41 (1.36-1.47) <.001 1.32 (1.14-1.54)
Model 2 0.506 0.035 270 0.178 <.001 1.39 (1.33-1.44) <.001 1.36 (1.16-1.59)
Model 3 0.487 0.035 116 0.184 <.001 1.40 (1.34-1.45) <.001 1.36 (1.16-1.61)
GRS2b
(FTO/MC4R)
Model 1 0.295 0.045 43.2 0.011 <.001 1.41 (1.36-1.47) <.001 1.22 (0.90-1.66)
Model 2 0.275 0.042 202 0.141 <.001 1.39 (1.33-1.44) <.001 1.18 (0.85-1.65)
Model 3 0.264 0.042 89.3 0.149 <.001 1.40 (1.34-1.45) <.001 1.18 (0.83-1.67)
a GRS1: Using de novo 13 SNPs obtained from GWAS    b GRS2: Using 13 candidate SNPs from the target genes (FTO and MC4R)
§ Binary outcome defined as serum aminotransferase (AST; Aspartate aminotransferase, or ALT; Alanine transaminase) level ≥ 40IU/L
Model 1: Crude model 
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, smoking status, alcohol drinking, and exercise status  
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Table 11. Association between body mass index and serum ALT§ level, among subjects without hepatitis B or C viral infection
Explanatory
variables
Outcome
variable
Instrumental
variable
Change in body mass index 
per increase of one risk allele or 
one unit of GRS
Observational 
multivariate 
linear regression 
analysis
Mendelian 
randomization 
analysis
β SE F R2 p β SE p βIV SE p
BMI
serum 
ALT levelc
1 SNP
(rs2030323)
Model 1 0.307 0.070 19.2 0.005 <.001 0.088 0.003 <.001 -0.004 0.041 0.916
Model 2 0.330 0.065 198 0.136 <.001 0.067 0.003 <.001 0.017 0.032 0.594
Model 3 0.313 0.066 88.3 0.144 <.001 0.068 0.003 <.001 0.017 0.035 0.634
GRS1a
Model 1 0.502 0.037 182 0.046 <.001 0.088 0.003 <.001 0.047 0.012 <.001
Model 2 0.506 0.035 270 0.178 <.001 0.067 0.003 <.001 0.051 0.011 <.001
Model 3 0.487 0.035 116 0.184 <.001 0.068 0.003 <.001 0.050 0.011 <.001
GRS2b
(FTO/MC4R)
Model 1 0.295 0.045 43.2 0.011 <.001 0.088 0.003 <.001 0.060 0.024 0.013
Model 2 0.275 0.042 202 0.141 <.001 0.067 0.003 <.001 0.046 0.024 0.052
Model 3 0.264 0.042 89.3 0.149 <.001 0.068 0.003 <.001 0.039 0.025 0.128
a GRS1: Using de novo 13 SNPs obtained from GWAS    b GRS2: Using 13 candidate SNPs from the target genes (FTO and MC4R)
c Log-transformed          § ALT, Alanine transaminase (continuous outcome)
Model 1: Crude model 
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, smoking status, alcohol drinking, and exercise status  
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5. Sensitivity analyses
GRS generated from the candidate SNPs (GRS2) was a much weaker IV than GRS1. 
Hence, it was difficult to confidently confirm the same conclusion with the main results 
from GRS1. The Mendelian randomization analysis using GRS2 for BMI, however,
assured the significant results of causal relationship between BMI and serum ALT level. 
All estimates from this type of GRS were also reported in Tables 8-11, along with the 
main results. When the same analyses excluding the heavy drinkers (N=3,268) and using 
the drinking amount information instead of drinking status were performed, the 
conclusion remained unchanged throughout the entire results (Tables 12-15).
Appendix B2 describes potential effects of genetic IVs (G) for serum adiponectin level or 
BMI on liver enzyme levels (Y), according to their effect sizes for each relevant 
intermediate phenotype. There was almost no change in effects (β coefficients) on the
liver enzyme levels, regardless of the changes in effect sizes of genetic variants for 
adiponectin levels. However, there was a small alteration in effects on the final outcome,
as SNPs showed different effect sizes on BMI.
A total of 36 and 37 SNPs that were significantly associated with elevated serum 
aminotransferase levels or serum ALT level (Y) in GWAS, respectively, were selected to 
conduct reciprocal analyses (Appendix A1 and A2). When the effects of these SNPs on 
exposure variables (X) were plotted, they revealed almost no effect on adiponectin levels
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(Appendix B3). Contrastively, these SNPs seemed to have an influence on BMI with a 
proportional nature to the effect sizes for outcome variables (Y). Calculation of LD r2 for 
every combination of SNPs on the same chromosome, across the groups of those 
determining adiponectin level, BMI, and liver enzyme levels, proved no evidence of any 
LD relationship.
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Table 12. Association between adiponectin and abnormal liver enzyme level§, among subjects without hepatitis B or C viral 
infection after exclusion of heavy drinkers
Explanatory
variables
Outcome
variable
Instrumental
variable
Change in 
log-transformed adiponectin
per increase of one risk allele or 
one unit of GRS
Observational 
multivariate 
logistic regression 
analysis
Mendelian 
randomization 
analysis
β SE F R2 p OR CI p OR CI
Adiponectinc
elevated 
serum
AST or ALT
1 SNP
(rs4783244)
Model 1 -0.182 0.015 150 0.045 <.001 0.38 (0.31-0.45) <.001 0.99 (0.42-2.35)
Model 2 -0.180 0.014 240 0.184 <.001 0.50 (0.41-0.61) <.001 1.02 (0.42-2.48)
Model 3 -0.179 0.014 99.7 0.184 <.001 0.49 (0.40-0.61) <.001 1.02 (0.41-2.53)
GRS1a
Model 1 -0.032 0.003 141 0.043 <.001 0.38 (0.31-0.45) <.001 0.76 (0.32-1.82)
Model 2 -0.033 0.003 237 0.186 <.001 0.50 (0.41-0.61) <.001 0.69 (0.29-1.63)
Model 3 -0.034 0.003 99.7 0.187 <.001 0.49 (0.40-0.61) <.001 0.68 (0.28-1.61)
GRS2b
(ADIPOQ)
Model 1 -0.059 0.008 56.3 0.017 <.001 0.38 (0.31-0.45) <.001 1.06 (0.27-4.23)
Model 2 -0.057 0.007 196 0.158 <.001 0.50 (0.41-0.61) <.001 1.20 (0.27-5.27)
Model 3 -0.056 0.007 82.1 0.158 <.001 0.49 (0.40-0.61) <.001 1.14 (0.25-5.20)
a GRS1: Using de novo 7 SNPs obtained from GWAS    b GRS2: Using 6 candidate SNPs from the target gene (ADIPOQ)
c Log-transformed          
§ Binary outcome defined as serum aminotransferase (AST; Aspartate aminotransferase, or ALT; Alanine transaminase) level ≥ 40IU/L
Model 1: Crude model 
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, smoking status, amount of alcohol drinking, and exercise status  
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Table 13. Association between adiponectin and serum ALT§ level, among subjects without hepatitis B or C viral infection
after exclusion of heavy drinkers
Explanatory
variables
Outcome
variable
Instrumental
variable
Change in 
log-transformed adiponectin 
per increase of one risk allele or 
one unit of GRS
Observational 
multivariate 
linear regression 
analysis
Mendelian 
randomization 
analysis
β SE F R2 p β SE p βIV SE p
Adiponectinc
serum 
ALT levelc
1 SNP
(rs4783244)
Model 1 -0.182 0.015 150 0.045 <.001 -0.281 0.016 <.001 -0.031 0.078 0.693 
Model 2 -0.180 0.014 240 0.184 <.001 -0.132 0.016 <.001 -0.007 0.071 0.919 
Model 3 -0.179 0.014 99.7 0.184 <.001 -0.131 0.016 <.001 -0.003 0.073 0.964 
GRS1a
Model 1 -0.032 0.003 141 0.043 <.001 -0.281 0.016 <.001 -0.020 0.082 0.809 
Model 2 -0.033 0.003 237 0.186 <.001 -0.132 0.016 <.001 -0.051 0.070 0.465 
Model 3 -0.034 0.003 99.7 0.187 <.001 -0.131 0.016 <.001 -0.053 0.071 0.453 
GRS2b
(ADIPOQ)
Model 1 -0.059 0.008 56.3 0.017 <.001 -0.281 0.016 <.001 -0.007 0.135 0.959 
Model 2 -0.057 0.007 196 0.158 <.001 -0.132 0.016 <.001 0.035 0.123 0.777 
Model 3 -0.056 0.007 82.1 0.158 <.001 -0.131 0.016 <.001 0.015 0.127 0.903 
a GRS1: Using de novo 7 SNPs obtained from GWAS    b GRS2: Using 6 candidate SNPs from the target gene (ADIPOQ)
c Log-transformed          § ALT, Alanine transaminase (continuous outcome)
Model 1: Crude model 
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, smoking status, amount of alcohol drinking, and exercise status  
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Table 14. Association between body mass index and abnormal liver enzyme level§, among subjects without hepatitis B or C 
viral infection after exclusion of heavy drinkers
Explanatory
variables
Outcome
variable
Instrumental
variable
Change in body mass index 
per increase of one risk allele or 
one unit of GRS
Observational 
multivariate 
logistic regression 
analysis
Mendelian
randomization 
analysis
β SE F R2 p OR CI p OR CI
BMI
elevated 
serum
AST or ALT
1 SNP
(rs2030323)
Model 1 0.297 0.076 15.3 0.004 <.001 1.42 (1.36-1.47) <.001 1.09 (0.92-1.29)
Model 2 0.313 0.071 167 0.133 <.001 1.40 (1.34-1.46) <.001 1.15 (0.87-1.51)
Model 3 0.290 0.072 75.2 0.142 <.001 1.41 (1.35-1.47) <.001 1.10 (0.65-1.87)
GRS1a
Model 1 0.512 0.040 162 0.048 <.001 1.42 (1.36-1.47) <.001 1.29 (1.10-1.52)
Model 2 0.514 0.038 230 0.177 <.001 1.40 (1.34-1.46) <.001 1.32 (1.12-1.57)
Model 3 0.499 0.038 101 0.184 <.001 1.41 (1.35-1.47) <.001 1.32 (1.11-1.57)
GRS2b
(FTO/MC4R)
Model 1 0.311 0.048 42.6 0.013 <.001 1.42 (1.36-1.47) <.001 1.24 (0.81-1.89)
Model 2 0.289 0.044 173 0.141 <.001 1.40 (1.34-1.46) <.001 1.20 (0.85-1.68)
Model 3 0.272 0.045 77.7 0.149 <.001 1.41 (1.35-1.47) <.001 1.21 (0.84-1.74)
a GRS1: Using de novo 13 SNPs obtained from GWAS    b GRS2: Using 13 candidate SNPs from the target genes (FTO and MC4R)
§ Binary outcome defined as serum aminotransferase (AST; Aspartate aminotransferase, or ALT; Alanine transaminase) ≥ 40IU/L
Model 1: Crude model 
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, smoking status, amount of alcohol drinking, and exercise status  
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Table 15. Association between body mass index and serum ALT§ level, among subjects without hepatitis B or C viral 
infection after exclusion of heavy drinkers
Explanatory
variables
Outcome
variable
Instrumental
variable
Change in body mass index 
per increase of one risk allele or 
one unit of GRS
Observational 
multivariate 
linear regression 
analysis
Mendelian 
randomization 
analysis
β SE F R2 p β SE p βIV SE p
BMI
serum 
ALT levelc
1 SNP
(rs2030323)
Model 1 0.297 0.076 15.3 0.004 <.001 0.087 0.003 <.001 -0.012 0.047 0.795
Model 2 0.313 0.071 167 0.133 <.001 0.068 0.003 <.001 0.006 0.038 0.866
Model 3 0.290 0.072 75.2 0.142 <.001 0.069 0.003 <.001 -0.006 0.043 0.892
GRS1a
Model 1 0.512 0.040 162 0.048 <.001 0.087 0.003 <.001 0.041 0.013 0.002
Model 2 0.514 0.038 230 0.177 <.001 0.068 0.003 <.001 0.044 0.012 <.001
Model 3 0.499 0.038 101 0.184 <.001 0.069 0.003 <.001 0.041 0.012 0.001
GRS2b
(FTO/MC4R)
Model 1 0.311 0.048 42.6 0.013 <.001 0.087 0.003 <.001 0.065 0.024 0.007
Model 2 0.289 0.044 173 0.141 <.001 0.068 0.003 <.001 0.050 0.024 0.035
Model 3 0.272 0.045 77.7 0.149 <.001 0.069 0.003 <.001 0.045 0.026 0.082
a GRS1: Using de novo 13 SNPs obtained from GWAS    b GRS2: Using 13 candidate SNPs from the target genes (FTO and MC4R)
c Log-transformed          § ALT, Alanine transaminase (continuous outcome)
Model 1: Crude model 
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, smoking status, amount of alcohol drinking, and exercise status  
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III. Discussion
1. Discussion of Study Results
In this population-based study, we provided evidence of a causal effect of obesity on 
elevation in serum aminotransferase level, which suggests hepatocyte injury. However, 
the results did not provide any consistent evidence for serum adiponectin as a causal 
factor for hepatocyte protection or reducing serum liver enzyme level.
A. Review of previous studies and biological plausibility: Adiponectin
Over the past decade, studies on the association among obesity, insulin sensitivity, and 
obesity-related metabolic disorders including fatty liver disease or NASH have been 
actively conducted, accompanied by suggestions of putative mechanisms; but most 
aspects are still unclear. One of the major controversies is the role and mechanism of 
adipokines such as adiponectin in the target organ. Some studies have implied these 
hormones may act as insulin sensitizers, which can reduce insulin resistance. Many 
researchers have even suggested the hormones as potential therapeutic or pharmacologic 
targets against diabetes or related disorders. Along with this claim, it has been argued that 
adiponectin protects liver cells from fat accumulation and fibrosis. This means it has an 
anti-steatotic, anti-inflammatory, and anti-fibrogenic effect and may lower the risk of 
fatty liver disease, as well as the risk of hepatocellular carcinoma.
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Results from observational studies and animal experiments have supported this 
claim.17,43,44 Nonetheless, previous studies were not free from confounders or reverse 
causation. Instead of using an experimental group that only differed from the control 
group in circulating adiponectin levels, genetically or pharmacologically manipulated 
obese and diabetogenic mice served as the experimental group.45 Therefore, to address 
these problems, some Mendelian randomization studies have been proposed to investigate 
the causal relationship between adiponectin and diabetes or related disease conditions.
The most recent Mendelian randomization study, which examined the association of 
blood adiponectin levels with insulin resistance and type 2 diabetes, was conducted on
about 30,000 (up to 31,000) subjects from 13 European studies in 2013.45 It was a large-
scale study that included the study group of 942 subjects,46 from which other researchers 
concluded that there is a causal relationship on the same topic, just before this study. In 
this larger study, researchers also used the genotype of the ADIPOQ gene and GRS; they 
argued that the causal association between adiponectin and insulin resistance or type 2 
diabetes could not be confirmed, because the IV analysis revealed that genetically 
determined low levels of adiponectin was not associated with increased insulin resistance 
and type 2 diabetes risk. This study added to the results of the animal study that showed 
genetically reduced adiponectin does not cause increased insulin resistance, and 
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suggested even a bidirectional relationship between insulin resistance and 
hypoadiponectinemia in humans.47
The authors of these studies explained it as follows: insulin resistance causes 
hyperinsulinemia, which in turn reduces serum adiponectin levels. Although such an 
explanation is inconsistent with the current view of adiponectin as an insulin-sensitizing 
hormone, it is supported by research that demonstrated decreased adiponectin level in 
participants under hyperinsulinemic conditions or receiving high-dose insulin infusion; 
other studies reported markedly elevated adiponectin level, (1) in people with functional 
loss of insulin receptors, which can be perceived as a constant hypoinsulinemic condition
even though it accompanies extremely high insulin resistance, or (2) in patients with type 
1 diabetes who actually exhibit low insulin levels.45,48-56
For the liver (when we extend the concept of insulin resistance to the liver), adiponectin 
has been regarded as having an inverse correlation with hepatic fat and hepatic insulin 
resistance in diabetic patients; in healthy people, low adiponectin concentration has been 
significantly associated with increased serum ALT and GGT levels, suggesting the role of 
adiponectin in hepatocyte injury or protection pathway.57-60 However, by focusing on the 
causal relationship, our study demonstrated that it was just an association rather than a 
prior contribution of adiponectin onto liver enzyme levels or hepatocyte injury. This 
conclusion also corresponds with the interpretations of previous study results, which 
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disagreed with a causal relationship between adiponectin level and systematic insulin 
resistance, along with several biological mechanisms.
B. Review of previous studies and biological plausibility: Obesity (BMI)
Likewise, there has been almost no Mendelian randomization study that directly 
investigated liver function or liver diseases as outcomes, with obesity or other similar 
conditions as a potential causal factor. However, the relationships between obesity as an 
exposure (potential cause of disease) and other abnormalities in cardiometabolic traits or 
associated diseases like fasting insulin level, triglyceride or HDL-cholesterol level, blood 
pressure, metabolic syndrome, type 2 diabetes, ischemic heart disease, or stroke as a 
respective outcome, have been tested through previous Mendelian randomization studies 
estimating whether they are causal associations or not.61-66 A relatively recent large-scale 
Mendelian randomization analysis regarding the association between elevated BMI and 
various cardiometabolic phenotypes has not only confirmed these causal relationships 
between adiposity and diverse cardiovascular diseases through the SNPs of the FTO gene, 
but has also provided new evidence for adiposity as a causal risk factor in relation with 
increased ALT and GGT.62
Results of the present study provides additional evidence for a causal relationship 
between obesity, assessed as BMI, and potential hepatocyte injury or liver disease, 
assessed by ALT and AST. Indeed, obesity is now recognized as a major independent risk 
52
factor for NAFLD.9 Although the initial point of alteration still remains controversial, 
insulin resistance in adipose, or peripheral tissue is considered to be the most critical and 
important factor in the pathogenesis of NAFLD.2,4,67 With regard to obesity, increased 
free fatty acids originating from excess adipose tissue inhibit the activation or expression 
of insulin receptors and glucose transporter proteins on the cell surface; along with 
inflammatory cytokine action produced by adipose tissues, insulin sensitivity decreases
and insulin resistance may occur.68
This insulin resistance, induced from abnormally enlarged inflammatory adipose tissue,
causes significant changes in lipid metabolism such as increased peripheral lipolysis, 
increased triglyceride synthesis, and increased fatty acid uptake in hepatocytes.2,69,70 The 
hepatic synthesis of triglycerides from fatty acids introduced from the blood, which is a 
basic function of liver cells that can be promoted by insulin,71,72 may be accelerated in 
patients with increased insulin resistance and subsequent hyperinsulinemia.
Both of the above actions can cause triglyceride accumulation in the liver, which in turn 
leads to a further shift in liver cell metabolism that induces change from the 
carbohydrates absorbed through the blood to the synthesis of fatty acids (de novo 
lipogenesis), and subsequently to the beta-oxidation of free fatty acids.71,72 Such a shift in 
hepatocyte metabolism, which predisposes them to generate more fatty acids from 
glucose and its derivatives, is also a process that can be promoted by insulin; it has been 
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reported that this shift toward fatty acid synthesis and oxidation is actually observed in 
patients with increased insulin resistance, supporting the suggested mechanism.71-74
All of the above explanations that link obesity to increased lipid accumulation and 
oxidation in the liver mediated by insulin resistance would be an important axis that 
explains much of the liver cell injury caused by obesity. To think about other causes that 
lead to elevated liver enzyme levels, we can completely rule out the possibility of 
hepatitis B or C viral infection from the study design step; we can also disregard the 
potential effects of alcohol to liver enzymes because it was adjusted for by statistical 
modeling or restricted from the start in sensitivity analyses. Hence, except for relatively 
rare or miscellaneous factors that lead to mild elevation in aminotransferase levels such as 
hemochromatosis, gallstones, and cholecystitis, hepatic steatosis and NASH are the
potential causes for slightly abnormal liver enzyme levels.8,75
Insulin resistance is considered to play an important role in the occurrence of NASH as 
well,76-78 but is not a feature of all NASH patients. Indeed, it has been documented that 
NASH is easily observed in patients who are not obese or have normal glucose tolerance,
and it is suggested that NASH could be a more heterogeneous disease that originating 
from one or more risk factors.2,76 In other words, NASH can develop through other 
mechanisms besides insulin resistance that occurs with hepatic lipid accumulation, in 
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contrast to simple steatosis that almost entirely develops from alterations in insulin 
sensitivity.
2. Discussion of Study Methods
By applying the Mendelian randomization approach, we were able to test for a causal 
relationship between adiposity, adiponectin, and elevation of liver enzymes, with the 
methodological strength in avoiding bias from potential confounders and reverse 
causation. Analyses were conducted within a relatively large study sample, which 
consisted of a randomly selected control group from the population-based cohort using 
the novel microarray chip reflecting ethnic specificity in genomic data for Korean people.
However, there are also several limitations regarding the Mendelian randomization
method.39 First, confounding of genotype-intermediate phenotype (i.e. exposure of 
interest) ‒ disease associations can occur. One of the mechanisms for this is LD, which 
refers to the association between different SNPs located in different loci. According to 
Smith and Ebrahim, the following two situations can bring about potential confounding in 
the study: if the SNPs determining the intermediate phenotype, or any other 
polymorphisms that are in LD with these SNPs, (1) affect the disease outcome directly 
through another pathway (by affecting through different ways to outcome, or affecting on 
common metabolic pathway that is related to both of the intermediate phenotype and the 
final outcome); or (2) affect the behavioral factors that may influence the final outcome 
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(through LD relationships between the SNPs affecting the intermediate phenotype and the 
SNPs affecting problematic behaviors, or through pleiotropic effects of those SNPs). 
These confounding caused by LD is closely linked with the third assumption of
Mendelian randomization analysis (presented in the methods section), also known as the
‘exclusion restriction’. However, it is known that this assumption cannot be fully verified 
empirically.79,80
To assess the problem of genetic LD in this study, we tested all LD values that can occur 
among the variants of two intermediate phenotypes (i.e. adiponectin level and BMI) and 
the final outcome (Figure 6). Since it was possible to list the SNPs that were significantly 
associated with these intermediate phenotypes and outcome variables (G1, G2 and G3), 
any LD among them could be directly observed through an appropriate analysis. All three 
combinations of SNPs located in the same chromosome demonstrated r2 of LD less than 
0.002 and were able to prove their mutual independences.
Another possible confounding factor in the genotype‒intermediate phenotype‒disease
relationship, other than LD, is population stratification. This confounding is related to a 
violation of the second assumption for the Mendelian randomization study. However, the 
study population used in this analysis was a relatively homogenous group, consisting of 
mono-ethnic healthy people who were confirmed to be negative for the HBV and HCV 
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virus infection; hence it was unlikely that different distributions in genotype, intermediate 
phenotype, and disease existed between subgroups of this study population.
Figure 6. Schematic expression of LD assessment (bidirectional arrows*) for genetic
variants affecting two intermediate phenotypes and the outcome of interest
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Second, pleiotropy and multi-function of genes can also exist. In the current study, the 
polymorphisms that influence adiponectin or BMI may also influence other phenotypes 
or a variety of pathophysiological processes, and involvement of such SNPs in the study 
would lead to some confusion in interpreting the final results by altering the effect size; it 
is difficult to interpret the association between genetic polymorphism and phenotypes 
under such a situation. 
These problems of confounding and pleiotropy could be assessed by measuring potential 
confounders in association with genetic data 81 as shown in Tables 6 and 7. Besides, a 
graphical approach described in Appendix B2 could suggest lower possibilities for the 
presence of other routes between the genetic IVs and the final outcome, particularly for 
the IVs of adiponectin level. In addition, results of reciprocal analyses (Appendix B3) 
implied that some of SNPs that determine liver enzyme levels would have an influence on 
BMI as well. They can be accepted as potential genetic confounders, and bidirectional
causal relationship may exist. Further study and analysis would be worth a try with an 
investigation for more clear relationships regarding those complex mechanisms (Figure 7).
Third, canalization or developmental compensation might occur when an organism is
influenced by a polymorphic genotype and altering the developmental process, such as 
during fetal development period to buffer against genetic effect. This problem is more 
difficult to study than other limitations mentioned above. However, most examples of 
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canalization are related to striking genetic or environmental insults, suggesting that single 
polymorphisms inducing just a small variation in phenotypes may not be sufficient to 
make compensatory changes.81
Fourth, the time-varying nature of the exposure variables, the possibility of gene-
environmental interaction, a measurement error in both exposure and outcome variables, 
and other potential biases could influence the study results. These biases have a greater 
possibility of influencing the results toward a false-positive, rather than a negative result
80; it is probably due to the majority of these biases could have differential nature of 
misclassification.
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(A)
(B)
Figure 7. Causal diagram and the result of Mendelian randomization analysis on
(A) serum adiponectin level and (B) body mass index for liver enzyme levels, with 
the findings of reciprocal approach, and LD assessment among the variants
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3. Comprehensive Discussion
There are some discussion points through the entire process of the study.
First, the lists of significant SNPs for adiponectin and BMI obtained from this study were 
quite different from those in previous studies. As for the GWAS results regarding 
adiponectin, only two SNPs of the ADIPOQ gene, which is the major adiponectin-related 
gene that has been reported mainly in Western populations, were included among the top 
20 SNPs; moreover, their effects were found to be weak. Most of the stronger effects 
were shown with the SNPs located on the CDH13 gene that has been mainly reported in 
Asian populations.82-85 Similarly, in the GWAS results regarding BMI, there were no 
significant SNPs from familiar obesity-related genes such as FTO or MC4R found on the 
list; however, a few SNPs on the BDNF gene, which has been reported in a relatively
small number of studies,86-89 were included in the top 20 SNPs list.
The following explanations would be applicable to these results: (1) they are ethnic-
specific results that obtained from the Asian (in particular, Korean) population, and (2) 
they are normal control group-specific outcomes derived from the sub-population 
consisting of participants who were confirmed as HBV and HCV-negatives, particularly 
within the Korean population in which the prevalence of chronic hepatitis virus infection 
is typically high. For the first sensitivity analysis regarding this problem, we obtained 
results from the Mendelian randomization analysis by using the separate sets of SNPs 
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selected from ADIPOQ,90,91 FTO and MC4R 92,93 gene regions, respectively, and 
compared them to the original results. For verification of the second hypothesis, we 
obtained GWAS results from the entire subcohort population prior to the selection of 
subjects who had negative result for hepatitis virus test. When comparing them with the 
original results, there was a clear difference in the BMI-related SNPs whereas 
adiponectin-related SNPs did not show significant differences. This BMI-related SNP list 
obtained from the entire subcohort included several polymorphisms located on the MC4R
gene.
Second, the effect of genotypes that determine the intermediate phenotype traits in the 
present study, especially for the BMI variable, seemed to polygenic, and this genetic 
heterogeneity could be a relative weakness in the genotype-exposure association.41
However, the significance or explanatory power of the genetic variables, estimated by the 
F statistic, was enough to perform the analysis, and it was well maintained even for the 
GRS, which was generated using multiple genetic variants.
Third, the low statistical power for the Mendelian randomization method was an 
inevitable limitation,81 which can be considered as a major cause of negative results in the 
analyses performed using single SNPs. However, by using multiple polymorphisms via 
combined single values of GRS, we were able to pull up the power of study and get 
positive results for estimation in regard to BMI.
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Fourth, as VanderWeele et al. suggested, Mendelian randomization design has very 
strong assumptions and asymmetric probability distribution between false negatives and 
false positives.80 This may result in negative results being more robust and valuable than 
positive results, granted that negative results would require a sufficiently large sample 
size in order to be reliable. When these conditions and assumptions are satisfied, the 
negative result for adiponectin in this study could be more meaningful.
Fifth, the methodologies for causal inference by controlling confounders based on the 
counterfactual model have a theoretical ability to control both the known and unknown 
confounders. However, in the field of epidemiology, it should be noted that this is just 
one of the approaches for causal inference. It is impossible to determine causation by any 
single method or study.94 The results of this study need to be understood based upon the 
strengths and limitations of the method used, as well as evaluated in the light of 
'pragmatic pluralism' and whether this approach was suitable for ‘inference to the best 
explanation’, according to the emphasis of experts.94,95
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IV. Conclusion
The present study investigated causal association using a population-based cohort 
composed of participants who had no prevalent disease and confirmed as negative to 
hepatitis B and C virus infection. Through Mendelian randomization analysis, we were 
able to provide evidence of a causal effect of obesity on elevation in serum 
aminotransferase levels, which suggests hepatocyte injury. However, the results did not 
provide any consistent evidence for serum adiponectin as a causal factor for hepatocyte 
protection or reducing serum liver enzyme level. The study results could not disprove the 
effectiveness of adiponectin or its suggested mechanism on metabolic traits. However, 
our findings help understand possible pathogenetic mechanisms that start from excessive 
adiposity and are linked to liver injury: obesity seems to be a causal factor, while 
decreased adiponectin seems to be an intermediate result rather than a cause.
The present study was the first Mendelian randomization study regarding liver damage 
assessed by aminotransferases levels in relation to obesity and adiponectin using genetic 
variants specific for the Asian population. According to our results, we suggest adiposity 
as the primary target for both preventive and therapeutic approaches regarding obesity-
related liver damage or metabolic liver diseases.
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Appendix
Appendix A. Supplementary Tables
A1. A list of 36 single nucleotide polymorphisms strongly relevant to the elevation of AST 
or ALT level (binary outcome)
Chr SNP
Risk 
allele
Other 
allele 
RAF
per allele 
odds ratio for 
elevated LFT
(≥ 40 IU/L)
per allele 
change in log-
transformed
adiponectin
per allele 
change in body 
mass index
OR 95% CI beta SE beta SE
18 rs148732782 A G 0.023 2.25 (1.60-3.16) -0.0383 (0.0425) 0.3704 (0.2265)
2 rs139657612 A G 0.013 2.84 (1.83-4.40) -0.0727 (0.0570) 0.8276 (0.3040)
17 rs9302960 G C 0.278 1.38 (1.20-1.59) -0.0042 (0.0147) 0.1446 (0.0779)
3 rs709157 A G 0.021 2.14 (1.49-3.07) -0.0210 (0.0451) 0.2036 (0.2385)
14 rs2877753 G A 0.394 1.39 (1.22-1.59) -0.0318 (0.0133) 0.1177 (0.0702)
3 rs9637430 C T 0.561 1.34 (1.17-1.54) -0.0145 (0.0130) 0.1039 (0.0692)
16 rs1558679 C T 0.076 1.59 (1.27-1.99) -0.0111 (0.0253) 0.0570 (0.1338)
17 rs4795294 A C 0.372 1.32 (1.15-1.50) 0.0122 (0.0135) 0.1117 (0.0717)
21 rs2836467 T C 0.028 1.99 (1.42-2.79) 0.0172 (0.0408) 0.1637 (0.2144)
10 rs138544218 T C 0.026 2.01 (1.43-2.84) 0.0474 (0.0411) -0.0275 (0.2193)
11 rs74493704 A C 0.012 2.58 (1.62-4.10) -0.0411 (0.0603) 0.1911 (0.3169)
6 rs9474312 T C 0.765 1.40 (1.19-1.66) -0.0002 (0.0152) 0.1620 (0.0805)
5 rs74436539 A G 0.017 2.34 (1.56-3.52) 0.0227 (0.0513) 0.4181 (0.2725)
16 rs147990649 T C 0.020 2.17 (1.48-3.19) 0.0515 (0.0481) 0.4875 (0.2505)
22 rs2281135 A G 0.412 1.33 (1.16-1.52) 0.0040 (0.0132) 0.0406 (0.0699)
2 rs60825457 A G 0.259 1.33 (1.15-1.54) -0.0403 (0.0150) 0.1508 (0.0793)
13 rs9556106 G A 0.535 1.32 (1.15-1.51) -0.0071 (0.0132) 0.0324 (0.0698)
22 rs5748561 T G 0.217 1.39 (1.19-1.62) 0.0089 (0.0159) 0.1883 (0.0841)
4 rs118080016 A C 0.028 2.07 (1.49-2.88) -0.0630 (0.0401) 0.0542 (0.2124)
8 rs77283999 A G 0.018 2.16 (1.45-3.23) 0.0260 (0.0502) 0.4158 (0.2641)
21 rs75497364 T C 0.046 1.71 (1.31-2.25) 0.0179 (0.0316) -0.0113 (0.1669)
2 rs13028301 C T 0.602 1.31 (1.14-1.51) 0.0021 (0.0133) 0.0837 (0.0706)
2 rs13003781 A G 0.583 1.31 (1.14-1.50) -0.0031 (0.0131) 0.1003 (0.0697)
18 rs9952685 A G 0.160 1.41 (1.19-1.65) -0.0171 (0.0174) 0.1632 (0.0923)
79
3 rs3773392 T C 0.589 1.33 (1.16-1.53) -0.0219 (0.0131) 0.0888 (0.0696)
20 rs6128136 A G 0.574 1.34 (1.16-1.54) -0.0120 (0.0135) 0.1602 (0.0712)
4 rs118007697 T C 0.021 2.19 (1.51-3.18) -0.0158 (0.0460) 0.4063 (0.2443)
8 rs7844770 A G 0.245 1.29 (1.11-1.50) -0.0011 (0.0153) 0.0452 (0.0809)
22 rs3761472 G A 0.404 1.31 (1.15-1.50) 0.0006 (0.0133) 0.0304 (0.0706)
1 rs10873661 A G 0.663 1.31 (1.13-1.51) -0.0034 (0.0139) 0.0154 (0.0735)
1 rs3790370 G A 0.301 1.32 (1.15-1.51) 0.0117 (0.0142) 0.0875 (0.0753)
3 rs17015485 A G 0.897 1.61 (1.25-2.08) -0.0133 (0.0219) 0.2171 (0.1155)
1 rs79622060 A C 0.046 1.49 (1.13-1.97) -0.0082 (0.0311) 0.3480 (0.1652)
11 rs118170751 G A 0.058 1.54 (1.21-1.97) -0.0038 (0.0275) 0.1805 (0.1463)
1 rs6682050 C T 0.155 1.36 (1.15-1.61) 0.0153 (0.0180) -0.0627 (0.0956)
15 rs149192877 G T 0.014 2.18 (1.40-3.41) 0.0071 (0.0554) 0.2103 (0.2934)
Adjusted for age, sex, and alcohol drinking status 
AST, Aspartate aminotransferase; ALT, Alanine transaminase; RAF, Risk allele frequency
LFT, Liver function tests, i.e. serum aminotransferase (AST or ALT) levels
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A2. A list of 37 single nucleotide polymorphisms strongly relevant to serum ALT level 
(continuous outcome)
Chr SNP
Risk 
allele
Other 
allele
RAF
per allele 
change in log-
transformed 
ALT
per allele 
change in log-
transformed
adiponectin
per allele 
change in body 
mass index
beta SE beta SE beta SE
12 rs671 G A 0.840 0.0546 (0.0169) 0.0035 (0.0180) 0.1067 (0.0953)
22 rs2281135 A G 0.412 0.0598 (0.0124) 0.0040 (0.0132) 0.0406 (0.0699)
12 rs2074356 G A 0.851 0.0544 (0.0175) -0.0087 (0.0186) 0.1205 (0.0984)
22 rs3761472 G A 0.404 0.0571 (0.0125) 0.0006 (0.0133) 0.0304 (0.0706)
22 rs12483959 A G 0.410 0.0557 (0.0125) 0.0102 (0.0133) 0.0523 (0.0701)
22 rs2143571 A G 0.409 0.0540 (0.0124) 0.0059 (0.0132) 0.0314 (0.0701)
22 rs2073080 T C 0.412 0.0514 (0.0124) 0.0044 (0.0132) 0.0326 (0.0697)
12 rs12229654 T G 0.857 0.0464 (0.0178) 0.0043 (0.0189) 0.0608 (0.1000)
12 rs12825782 C T 0.947 0.0848 (0.0280) -0.0158 (0.0297) 0.0842 (0.1576)
3 rs141040283 A G 0.021 0.1473 (0.0434) -0.0331 (0.0460) 0.8132 (0.2435)
10 rs72794433 A G 0.853 0.0778 (0.0177) -0.0159 (0.0187) 0.2418 (0.0994)
12 rs11066453 A G 0.874 0.0591 (0.0189) 0.0135 (0.0200) 0.0267 (0.1062)
17 rs16976928 C T 0.911 0.0840 (0.0217) -0.0212 (0.0229) 0.3346 (0.1218)
3 rs13066322 T C 0.366 0.0397 (0.0129) -0.0189 (0.0137) 0.1538 (0.0723)
2 rs4853928 C T 0.071 0.0981 (0.0242) -0.0529 (0.0257) 0.3306 (0.1363)
18 rs2846607 G A 0.747 0.0533 (0.0143) -0.0088 (0.0152) 0.0987 (0.0804)
9 rs3124299 C T 0.576 0.0510 (0.0126) -0.0138 (0.0133) 0.1120 (0.0710)
14 rs148953101 T C 0.017 0.1435 (0.0479) 0.0282 (0.0507) 0.3835 (0.2692)
11 rs78043680 A G 0.018 0.1652 (0.0474) 0.0132 (0.0498) 0.5443 (0.2661)
12 rs2072134 G A 0.882 0.0613 (0.0194) 0.0053 (0.0205) 0.0100 (0.1091)
2 rs60825457 A G 0.259 0.0460 (0.0141) -0.0403 (0.0150) 0.1508 (0.0793)
11 rs118043978 A G 0.049 0.0973 (0.0288) -0.0164 (0.0306) 0.0269 (0.1617)
6 rs9474312 T C 0.765 0.0481 (0.0143) -0.0002 (0.0152) 0.1620 (0.0805)
1 rs34110867 C T 0.139 0.0488 (0.0178) 0.0067 (0.0188) 0.0839 (0.1000)
14 rs11159377 C A 0.116 0.0761 (0.0194) -0.0060 (0.0205) 0.1547 (0.1089)
22 rs6006611 G A 0.523 0.0497 (0.0124) 0.0032 (0.0131) 0.0295 (0.0695)
10 rs7083899 A G 0.091 0.0963 (0.0214) -0.0303 (0.0228) 0.1360 (0.1204)
17 rs9302960 G C 0.278 0.0469 (0.0139) -0.0042 (0.0147) 0.1446 (0.0779)
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14 rs17094134 T C 0.905 0.0819 (0.0213) -0.0502 (0.0225) 0.0904 (0.1200)
7 rs140414042 A C 0.014 0.1742 (0.0532) 0.0120 (0.0564) 0.2838 (0.2987)
10 rs12360216 A G 0.083 0.0801 (0.0222) -0.0409 (0.0236) 0.2513 (0.1247)
4 rs76520795 C T 0.943 0.1024 (0.0274) -0.0288 (0.0290) 0.2333 (0.1543)
12 rs12580178 A G 0.131 0.0760 (0.0183) -0.0429 (0.0194) 0.2022 (0.1028)
2 rs997451 C A 0.038 0.1042 (0.0317) -0.0342 (0.0335) 0.1344 (0.1782)
5 rs34224742 G A 0.974 0.1223 (0.0389) -0.0395 (0.0413) 0.3842 (0.2188)
4 rs118007697 T C 0.021 0.1699 (0.0434) -0.0158 (0.0460) 0.4063 (0.2443)
6 rs960298 G A 0.588 0.0383 (0.0124) 0.0102 (0.0132) 0.1320 (0.0699)
Adjusted for age, sex, and alcohol drinking status 
ALT, Alanine transaminase; RAF, Risk allele frequency
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Appendix B. Supplementary Figures
B1. Manhattan plots of the p-values regarding (A) serum adiponectin level and (B) body 
mass index
(A)
(B)
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B2.
Effects (β coefficients) of (A) serum adiponectin and (B) body mass index determining 
SNPs on the risk of LFT elevation and serum ALT level
(A)
LFT, Liver function tests, i.e. serum aminotransferase (both of AST and ALT) levels;
AST, Aspartate aminotransferase; ALT, Alanine transaminase
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(B)
LFT, Liver function tests, i.e. serum aminotransferase (both of AST and ALT) levels;
AST, Aspartate aminotransferase; ALT, Alanine transaminase
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B3.
Reciprocal associations between outcome and exposure variables: effects (β coefficients) 
of (A) LFT elevation or (B) serum ALT level determining SNPs on serum adiponectin 
levels and body mass index
(A)
LFT, Liver function tests, i.e. serum aminotransferase (both of AST and ALT) levels;
AST, Aspartate aminotransferase; ALT, Alanine transaminase
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(B)
LFT, Liver function tests, i.e. serum aminotransferase (both of AST and ALT) levels;
AST, Aspartate aminotransferase; ALT, Alanine transaminase
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KOREAN ABSTRACT
Mendelian Randomization 분석을 이용한
아디포넥틴과 체질량지수, 혈청 아미노전이효소 간
인과성 추론
배경 및 연구목적
비만과 간 세포 손상 간의 관련성은 많은 연구들을 통해 밝혀져 왔으며, 
아디포카인의 한 종류인 아디포넥틴은 간 세포에 대해서 지방질 축적 및
섬유화 또는 간 경화로부터의 보호 작용 가능성이 제기됨에 따라 다양한
연구의 대상이 되어 왔다. 그럼에도 불구하고, 관찰 연구의 한계로 인해
비만과 아디포넥틴, 그리고 간 질환 사이의 연관 관계에 대한 인과성은
입증될 수 없었다. 이 연구에서는 일반 인구집단 대상의 코호트 자료를
이용하여, 유전 형질을 도구변수로 활용한 Mendelian Randomization 방법을
통해 비만과 아디포넥틴 수치가 혈청 아미노전이효소 상승과 인과적 관련성을
가지는지를 평가하였다.
연구 대상과 방법
한국인 암 예방 연구 II (KCPS-II) 바이오뱅크의 정상인 서브코호트에 속한
혈청 아미노전이효소 수치 120IU/L 이하의 간염 바이러스 검사 음성 판정자
3,793 명을 대상으로, 아디포넥틴 수치 및 체질량지수에 대한 전장유전체
연관분석(Genome-wide association study, GWAS)을 시행하였다. 노출변수, 
즉 중간 표현형과 높은 연관성을 보인 단일염기다형성(single nucleotide 
polymorphism, SNP) 혹은 가중치를 부여하여 통합한 유전위험점수(weighted
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genetic risk score)가 Mendelian randomization 분석을 위한 도구변수로
사용되었다. 간 효소 수치 상승에 대한 노출변수의 인과적 영향력은 Wald 
방법과 2 단계 최소자승법(two-stage least squares, 2SLS)을 통해 측정되었다.
연구 결과
CDH13 유전자의 rs4783244 와 그 외 7 개의 상호 독립적인 SNP 가
아디포넥틴 수치와 높은 연관성을 보이는 유전 도구변수로 선정되었으며, 
BDNF 유전자의 rs2030323 을 포함한 13 개의 독립적인 SNP 가 체질량지수에
대한 유전 도구변수로 선정되었다. 분석에 사용된 단일염기다형성과
유전위험점수는, 각 중간 표현형과의 강한 관련성 및 높은 설명력을
보여주었다. 관찰연구에서의 전통적 분석 방법에서는 유의하였던 아디포넥틴
수치와 간 효소 상승 간 연관성은 Mendelian randomization 분석에서는
유의하지 않은 결과를 보인 반면, 체질량지수로 표현된 비만과 간 효소
상승과의 관련성은 Mendelian randomization 분석을 통해서도 유의하게
입증되어 두 요소 간의 인과성을 지지하였다.
결론
본 연구는 Mendelian randomization 분석을 이용한 인과성 추론을 통해, 
체내 과도한 지방이 간 세포 손상을 초래하는 원인으로 작용하며, 낮은
아디포넥틴 수치는 원인이 되기보다는 이러한 과정에서 나타나는 중간
결과임을 제시하였다. 이는 비만 혹은 대사증후군과 관련된 간 손상 또는
간질환의 예방과 치료에 있어서, 일차적 목표는 아디포넥틴의 증가가 아닌
체지방의 감소가 되어야 함을 시사한다는 점에서 그 의의를 지닌다.
핵심어: 아디포넥틴, 체질량지수, 간기능검사, Mendelian Randomization 분석, 
유전위험점수
